• Targeted
    Immuno-Oncology Platform
    ACT-901 | ACT-902 | ACT-903
    Learn More
  • Immunotherapy Platform
    ACT-101
    Learn More
  • Targeted
    Immuno-Oncology Platform
    ACT-901 | ACT-902 | ACT-903
    Learn More
  • Immunotherapy Platform
    ACT-101
    Learn More

Harnessing Nature To Beat Cancer

Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with platform technologies in Immunotherapy and Immuno-Oncology. These platforms under development treat auto-immune disease indications and cancer. The company’s drug products use our proprietary recombinant human alpha fetoprotein (AFP).

Bristol-Myers Squibb is a 14% equity shareholder with no other commercial rights.

News

April 15, 2022

Alpha Cancer Technologies Inc. Announces Acceptance of Abstract for Online Publication at the 2022 American Society of Clinical Oncology Annual Meeting

Press Release
Abstracts will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 26, 2022

click https://themauimiracle.org/bonus/would-viagra-work-on-a-paraplegic/64/ pastile asemanatoare cu viagra synthroid drug interaction ramanujan essay dapoxetine and premature ejaculation essay grabber good essay writing cheap creative essay ghostwriters service ca essay on my favourite journey essay topics about immigration https://www.carrollkennelclub.org/phrasing/format-of-report-writing-essay/6/ cisti funzionali clomid side https://lincolnnova.com/dailyuse/viagra-me-da-dolor-de-cabeza/83/ case study methodology robert yin how nuch do 25mg generac viagra cost? reaction to sulfu in biaxin https://zacharyelementary.org/presentation/describe-essay-my-room/30/ dissertation virtual learning environment https://samponline.org/blacklives/child-enthroned-essay-free-get-madonna/27/ osu viagra bestellen goedkoop argumentative essay about racism https://aaan.org/indications/hydrochlorothiazide-treats/27/ superkamagra with dapoxetine definition essay for freedom https://sfiec.edu/pdf/?docx=essays-by-famous-american-writers source quel dosage pour le cialis kamagra kruidvat tom kaulitz tem overdose viagra source site roman fever essay Toronto, Canada, April 14, 2022 —   Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced that an abstract the company submitted has been accepted by American Society of Clinical Oncology (ASCO) for the 2022 ASCO Annual Meeting and will be published in an online supplement of the Journal of Clinical Oncology following the meeting. ASCO will be held in Chicago from June 3-8, 2022.

This year, ASCO received and reviewed more than 6,000 abstracts for the 2022 ASCO Annual Meeting. For more information about the Annual Meeting, please visit: https://conferences.asco.org/am/attend. Per ASCO’s Embargo & Release Information, abstracts will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 26, 2022.

September 16, 2021

Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-maytansine Conjugate, at 2021 European Society of Medical Oncology Annual Meeting

Press Release

Preclinical studies show ACT-903 demonstrates tumor suppression, increased survival, maytansine and metabolite accumulation in the tumor, and no signs of toxicity

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced the presentation of new preclinical data from the Company’s investigational therapy, ACT-903 at the European Society of Medical Oncology (ESMO) Annual Meeting being held virtually September 16-21, 2021.

View Full Press Release
View Poster

August 17, 2021

AFP-Maytansine Conjugate – a Novel Targeted Cancer Immunotherapy

Press Release

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein platform, today announced that its abstract featuring data from the Company’s investigational therapy, ACT-903, has been selected for presentation at the European Society of Medical Oncology (ESMO) Annual Meeting being held virtually September 16-21, 2021.

Details about the abstract selected for poster publication can be found below:

Title: AFP-Maytansine Conjugate – a Novel Targeted Cancer Immunotherapy
Abstract Number: 523P
Authors: I. Sherman, R. Boohaker, K. Stinson, P. Griffin, W. Hill
Abstracts are under embargo until 5:00 p.m. ET on Sept. 15, 2021.

For more information about the Annual Meeting, please visit: https://www.esmo.org/meetings/esmo-congress-2021

July 21, 2020

Alpha Cancer Technologies to License AbSci’s SoluPro Strain for the Expression of Alpha-Fetoprotein

Press Release

AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost biomanufacturing of difficult-to-produce biotherapeutics, today announced that it has entered into an agreement to license its E. coli SoluPro® protein expression technology to Alpha Cancer Technologies for the production of Recombinant Human Alpha-fetoprotein (hAFP). hAFP is a natural human protein produced by human embryo and yolk sac during development and can be used in the treatment of various autoimmune diseases and cancers. This license is an expansion of a previous collaboration between the parties that began last year.

Download

October 17, 2017

Study Results of ACT-101 in a Model of Inflammatory Bowel Disease (IBD) Presented at the World Congress of Gastroenterology 2017

Press Release

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on therapies for patients with autoimmune diseases and cancer, today announced the results of a study of ACT-101 (recombinant human alpha fetoprotein or rhAFP) in the treatment of Inflammatory Bowel Disease (IBD) at the World Congress of Gastroenterology 2017, held in partnership with The American College of Gastroenterology in Orlando, Florida. The study was sponsored by ACT to corroborate published clinical trial results using native human AFP.

Download